Savara INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

13 Mar 2026

SVRA

10-K: Savara's MOLBREEVI BLA Filed, Granted Priority Review

Savara Inc. announced its Biologics License Application for MOLBREEVI in autoimmune PAP was formally filed by the FDA and granted Priority Review in February 2026, following a resubmission in December 2025 after an initial Refusal to File letter.

NASDAQ

25 Apr 2025

SVRA

Savara INC

10-K/A: Savara Inc. Files Amendment to 10-K to Include Insider Trading Policy

Savara Inc. files an amendment to its annual report on Form 10-K to include its Insider Trading and Disclosure Policy, which was inadvertently omitted from the original filing.

NASDAQ

27 Mar 2025

SVRA

Savara INC

10-K: Savara Inc. Completes BLA Submission for Molgramostim, Secures $200 Million Debt Facility

Savara Inc. finalizes its biologics license application to the FDA for molgramostim and secures a $200 million debt facility to advance its rare respiratory disease program.

NASDAQ

7 Mar 2024

SVRA

Savara INC

10-K: Savara Inc. 10-K Filing: Focus on Molgramostim Development and Financial Health

Savara Inc.'s 10-K filing highlights the company's focus on its sole product candidate, molgramostim, for treating autoimmune pulmonary alveolar proteinosis (aPAP), while also detailing its financial position and risks.